How did RANI's operating expenses trend in Q4 2024?

Rani Therapeutics Holdings Inc.'s operating expenses for Q4 2024 are not currently available. However, the latest available data is from Q3 2024, where the company reported a decrease in operating expenses.

1. **Comparison with Previous Quarters**: Operating expenses for the nine months ended September 30, 2024, were $38.4 million, marking a decrease of 27.2% compared to the same period in 2023, driven by lower compensation costs and reduced third-party services.
2. **Trend Analysis**: The trend in operating expenses has been decreasing, with a 33.9% reduction in expenses for the three months ended September 30, 2024, compared to the same period in 2023, primarily due to reductions in workforce and third-party services.

In conclusion, Rani Therapeutics Holdings Inc. has demonstrated a decreasing trend in operating expenses, which aligns with the company's strategic cost-management initiatives.